A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

Official title

A First-in-Human Phase 1, Open-label, Two-stage, Randomized Trial to Assess the Safety, Tolerability, and Biodistribution of [177Lu]Lu-ABY-271 in Tumors and Critical Organs in Subjects With HER2-positive Metastatic Breast Cancer

Overview

This is a FiH phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of \[177Lu\]Lu-ABY-271 in subjects with HER2 positive metastatic breast cancer.

Detailed description

The trial consists of two parts:

Part A in which the uptake of \[177Lu\]Lu-ABY-271 in tumors and critical organs will be evaluated and up to 6 subjects will be enrolled sequentially.

Part B in which the optimal protein mass dose range (mg) to be utilized in subsequent clinical trials will be evaluated. 15 subjects will be randomized to 3 different protein mass dose levels (1:1:1), divided into two sequential cohorts with different radioactivity levels.

Interventions

• Drug [177Lu]Lu-ABY-271
  A single infusion of \[177Lu\]Lu-ABY-271

Primary outcome measures

• Treatment emergent adverse events [Time frame: From baseline to the end-of-trial visit, for part A Day 29 and for part B Day 43]
• Dose Limiting Toxicities [Time frame: From baseline to the end-of-trial visit, for part A Day 29 and for part B Day 43]

Secondary outcome measures (3)

• Absorbed dose in gray (Gy) per organ and selected tumors [Time frame: From baseline to day 8]
• Absorbed dose coefficient (Gy/GBq) per organ and selected tumors [Time frame: From baseline to day 8]
• Normalized whole-body effective dose (millisieverts [mSv]/MBq) [Time frame: From baseline to day 8]

Eligibility criteria

Inclusion criteria

• Subject has unresectable locally advanced or metastatic breast cancer
• Subject with histologically or cytologically confirmed carcinoma with documented HER2 overexpression (biopsy not older than 2 years): immunohistochemistry (IHC) score 3+; OR 2+ and fluorescence in situ hybridization (ISH) positive
• At least one known tumor lesion ≥ 15 mm
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

Part A only

\- Subject is in treatment, or planned to start a new line of standard systemic anti-tumor therapy

Part B only

• Subject has progressive disease, documented radiologically in the last three months
• Subject has received at least 3 lines of standard systemic anti-tumor therapy in the palliative setting
• Subject has received last dose of previous line of systemic anti-tumor therapy, and has no ongoing treatment related toxicities > grade 1 (except alopecia) prior to planned first dose of \[177Lu\]Lu-ABY-271

Exclusion criteria

• Active brain metastases
• Administration of another IMP within 5 half-lives (for experimental biologics: 6 months or 5 half-lives, whichever is longer) of the planned first dose of \[177Lu\]Lu-ABY-271
• Exposure to any anti-tumor therapy since the last documented progression, including any radiotherapy within 7 days prior to the planned first dose of \[177Lu\]Lu-ABY-271

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

Sweden · 3 centers

• Sahlgrenska University Hospital — Gothenburg
• Karolinska University Hospital — Stockholm
• Akademiska Sjukhuset — Uppsala

Identifiers

NCT: NCT07081555 · Affibody AB

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗